---
title: "Optimizing mAb Purification: A Fast, Efficient Two-Step Process Using a Weak AEX-HIC Mixed-Mode Resin"
description: Streamline mAb purification with Nuvia wPrime 2A mixed-mode resin, reducing chromatography steps, costs, and processing time while maintaining quality.
---

[![BPI Media\_Logo 2\_Color 1](https://bpi.bioprocessintl.com/hs-fs/hubfs/BPI%20Media_Logo%202_Color%201.png?width=350&height=161&name=BPI%20Media_Logo%202_Color%201.png)](https://bioprocessintl.com/)

# ![BPI Media\_AsktheExpert\_590 x 197\_Header\_for\_Landing\_Pages](https://bpi.bioprocessintl.com/hs-fs/hubfs/BPI%20Media_AsktheExpert_590%20x%20197_Header_for_Landing_Pages.jpg?width=543&height=181&name=BPI%20Media_AsktheExpert_590%20x%20197_Header_for_Landing_Pages.jpg)

# Optimizing mAb Purification:

# A Fast, Efficient Two-Step Process

# Using a Weak AEX-HIC Mixed-Mode Resin

|  |
| --- |

## Presenter:

**![08-28-2025-Bio-Rad-ATE-Speaker-HS-Cropped](https://bpi.bioprocessintl.com/hs-fs/hubfs/08-28-2025-Bio-Rad-ATE-Speaker-HS-Cropped.png?width=160&height=226&name=08-28-2025-Bio-Rad-ATE-Speaker-HS-Cropped.png)**

**Marian Magdy**

*R&D Purification Manager,*

Minapharm Pharmaceuticals 

 

Marian Magdy is a biopharmaceutical professional with almost 17 years of experience in the industry. As a pharmacy graduate in 2001, Marian began her career at the Central Administration of Pharmaceutical Affairs, where she worked until 2008. In 2009, she joined Minapharm as a downstream processing specialist in the research and development lab, advancing through the ranks to be the head of the downstream department starting 2019. In 2025, she was promoted to be the manager of the department. Today, Marian leads the development of the downstream process of several projects including monoclonal antibodies, hormones, and vaccines. She also contributed in the technology transfer and the upscale of several projects to the commercial scale.

## About this event:

#### Date: October 8, 2026

#### Time: 11 am EDT | 8 am PDT | 5 pm CEST

#### Duration: 15 minutes

| Monoclonal antibodies (mAbs) constitute a major segment of the biopharmaceutical industry product pipeline. However, their purification presents challenges such as high production costs, the need for robust processes to ensure product purity and viral clearance, and efficient integration of upstream and downstream operations. The standard mAb purification process typically involves three chromatography steps. It begins with Protein A chromatography for product capture, followed by two additional chromatography steps to remove host cell proteins, DNA, charge variants, and aggregates. A more efficient alternative involves using Nuvia wPrime 2A Media, a mixed-mode chromatography resin, essentially eliminating the need of one chromatography step after Protein A capture. This significantly reduces production costs by lowering process time, buffer consumption, and media expenses while enhancing overall product yield without compromising product quality specifications. Additionally, the weak anion exchange-hydrophobic interaction mixed-mode chromatography step can be operated in a flow-through mode, offering greater flexibility in binding capacity, flow rates, and processing times. Key Takeaways: - Lower costs and improve efficiency by reducing purification steps. - Simplify downstream processing with flow-through mixed-mode chromatography. - Increase process flexibility while maintaining product quality. |
| --- |

 

©2015 BioProcess International All Rights reserved